ScinoPharm Taiwan, Ltd. (1789.TW)
TWD 18.75
(3.88%)
TWD 18.75
(3.88%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 621.1 Million TWD | -8.38% |
| 2022 | 677.9 Million TWD | 21.58% |
| 2021 | 557.6 Million TWD | -3.42% |
| 2020 | 577.34 Million TWD | -31.38% |
| 2019 | 841.38 Million TWD | -40.45% |
| 2018 | 1.41 Billion TWD | -16.55% |
| 2017 | 1.69 Billion TWD | -5.24% |
| 2016 | 1.78 Billion TWD | 4.9% |
| 2015 | 1.7 Billion TWD | 33.21% |
| 2014 | 1.27 Billion TWD | 85.08% |
| 2013 | 690.86 Million TWD | 160.98% |
| 2012 | 264.72 Million TWD | 318840.96% |
| 2011 | 83 Thousand TWD | -97.31% |
| 2010 | 3.08 Million TWD | -99.52% |
| 2009 | 643.99 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 667.61 Million TWD | 7.49% |
| 2024 Q2 | 654.44 Million TWD | -1.97% |
| 2023 Q1 | 686.57 Million TWD | 1.28% |
| 2023 Q3 | 650.46 Million TWD | -3.69% |
| 2023 Q4 | 621.1 Million TWD | -4.51% |
| 2023 Q2 | 675.36 Million TWD | -1.63% |
| 2023 FY | 621.1 Million TWD | -8.38% |
| 2022 Q4 | 677.9 Million TWD | 4.37% |
| 2022 Q2 | 627.04 Million TWD | 0.77% |
| 2022 Q1 | 622.23 Million TWD | 11.59% |
| 2022 FY | 677.9 Million TWD | 21.58% |
| 2022 Q3 | 649.54 Million TWD | 3.59% |
| 2021 Q2 | 603.45 Million TWD | -0.69% |
| 2021 Q4 | 557.6 Million TWD | -0.52% |
| 2021 Q1 | 607.63 Million TWD | 5.25% |
| 2021 FY | 557.6 Million TWD | -3.42% |
| 2021 Q3 | 560.49 Million TWD | -7.12% |
| 2020 Q4 | 577.34 Million TWD | -13.6% |
| 2020 Q2 | 604.06 Million TWD | -30.84% |
| 2020 Q1 | 873.45 Million TWD | 3.81% |
| 2020 FY | 577.34 Million TWD | -31.38% |
| 2020 Q3 | 668.22 Million TWD | 10.62% |
| 2019 Q3 | 880.62 Million TWD | -61.09% |
| 2019 Q4 | 841.38 Million TWD | -4.46% |
| 2019 Q2 | 2.26 Billion TWD | -0.99% |
| 2019 Q1 | 2.28 Billion TWD | 61.76% |
| 2019 FY | 841.38 Million TWD | -40.45% |
| 2018 Q4 | 1.41 Billion TWD | -15.19% |
| 2018 FY | 1.41 Billion TWD | -16.55% |
| 2018 Q1 | 1.74 Billion TWD | 3.03% |
| 2018 Q2 | 1.78 Billion TWD | 2.11% |
| 2018 Q3 | 1.66 Billion TWD | -6.48% |
| 2017 Q1 | 1.73 Billion TWD | -2.73% |
| 2017 FY | 1.69 Billion TWD | -5.24% |
| 2017 Q4 | 1.69 Billion TWD | -10.43% |
| 2017 Q3 | 1.89 Billion TWD | 4.15% |
| 2017 Q2 | 1.81 Billion TWD | 4.43% |
| 2016 FY | 1.78 Billion TWD | 4.9% |
| 2016 Q3 | 1.76 Billion TWD | 1.6% |
| 2016 Q2 | 1.74 Billion TWD | 0.24% |
| 2016 Q1 | 1.73 Billion TWD | 1.94% |
| 2016 Q4 | 1.78 Billion TWD | 1.03% |
| 2015 Q1 | 1.39 Billion TWD | 9.2% |
| 2015 FY | 1.7 Billion TWD | 33.21% |
| 2015 Q4 | 1.7 Billion TWD | 0.95% |
| 2015 Q3 | 1.68 Billion TWD | 13.25% |
| 2015 Q2 | 1.48 Billion TWD | 6.7% |
| 2014 Q3 | 1.12 Billion TWD | 11.72% |
| 2014 Q4 | 1.27 Billion TWD | 13.69% |
| 2014 FY | 1.27 Billion TWD | 85.08% |
| 2014 Q2 | 1 Billion TWD | -6.0% |
| 2014 Q1 | 1.07 Billion TWD | 55.01% |
| 2013 Q3 | 743.59 Million TWD | -1.56% |
| 2013 FY | 690.86 Million TWD | 160.98% |
| 2013 Q1 | 392.82 Million TWD | 48.39% |
| 2013 Q2 | 755.36 Million TWD | 92.29% |
| 2013 Q4 | 690.86 Million TWD | -7.09% |
| 2012 Q4 | 264.72 Million TWD | 551402.08% |
| 2012 FY | 264.72 Million TWD | 318840.96% |
| 2012 Q2 | 68 Thousand TWD | 33.33% |
| 2012 Q1 | 51 Thousand TWD | -38.55% |
| 2012 Q3 | 48 Thousand TWD | -29.41% |
| 2011 Q3 | 240 Thousand TWD | -59.87% |
| 2011 Q4 | 83 Thousand TWD | -65.42% |
| 2011 Q2 | 598 Thousand TWD | 0.0% |
| 2011 FY | 83 Thousand TWD | -97.31% |
| 2010 FY | 3.08 Million TWD | -99.52% |
| 2010 Q4 | 3.08 Million TWD | 0.0% |
| 2009 FY | 643.99 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 192.92 Million TWD | -221.948% |
| Standard Chem & Pharm CO., LTD. | 1.08 Billion TWD | 42.597% |
| Maywufa Company Ltd. | 442.66 Million TWD | -40.31% |
| Lotus Pharmaceutical Co., Ltd. | 11.58 Billion TWD | 94.639% |
| LIWANLI Innovation Co., Ltd. | 2.63 Million TWD | -23462.329% |
| YungShin Global Holding Corporation | 1.23 Billion TWD | 49.888% |
| PhytoHealth Corporation | 28.11 Million TWD | -2109.152% |
| SCI Pharmtech, Inc. | 1.04 Billion TWD | 40.42% |
| Formosa Laboratories, Inc. | 4.06 Billion TWD | 84.718% |
| PharmaEssentia Corporation | 1.2 Billion TWD | 48.251% |
| Bora Pharmaceuticals Co., LTD. | 5 Billion TWD | 87.602% |